The verdict
Our read at a glance.
Whether difelikefalin is understood as an approved treatment for the specific itch of dialysis-related kidney disease, working through peripheral kappa-opioid receptors, rather than a general anti-itch or pain drug.
- The signal
- Randomized trials (KALM-1 and KALM-2) showed difelikefalin reduced itch intensity in hemodialysis patients with moderate-to-severe chronic-kidney-disease itch compared with placebo, with meaningful relief for many.
- The unknown
- How well it works beyond dialysis-related itch (other forms of chronic itch are being studied), how durable the relief is, and its place against other itch treatments.
- Our read
- A genuinely clever peptide for a real, neglected problem: it taps kappa-opioid receptors to quiet dialysis-related itch while being engineered to stay out of the brain, so it sidesteps opioids' addiction and breathing risks. The benefit is real but modest-to-meaningful, and it is approved specifically for itch in hemodialysis patients, not a general itch or pain drug.
The mechanism
How it works.
Itch is carried by specific nerves and tuned by the body's opioid system, where two receptor types pull in opposite directions: mu-opioid receptors (the target of morphine) can worsen itch, while kappa-opioid receptors tend to suppress it. Difelikefalin is a small synthetic peptide that switches on kappa-opioid receptors. It was deliberately built to be water-loving so it stays mostly in the body's periphery and barely enters the brain, acting on kappa receptors on sensory nerves and immune cells to turn down the itch signal, while avoiding the high, sedation, and dependence that come from drugs acting on the brain's opioid receptors. It is given into the bloodstream at the end of dialysis.
Safety & regulatory boundary
The consequential part.
Difelikefalin is generally well tolerated; reported effects include diarrhea, dizziness, drowsiness, and, in this frail dialysis population, occasional unsteadiness or changes in alertness, plus high potassium. Because it is a kappa-opioid (not a morphine-like mu-opioid) and stays largely outside the brain, it is not a controlled substance and lacks the usual opioid addiction and breathing risks. It is approved only for itch in adults on hemodialysis, given by a clinician at dialysis, not as a general painkiller or itch remedy. Korsuva is the brand for that use.
What's next
What we're watching.
Results in other types of chronic itch (including an oral form), long-term effectiveness, and comparisons with other antipruritic approaches.
Context
Why this is discussed.
Relentless itching is a common, miserable, and under-treated problem for people on dialysis. Difelikefalin is a clever peptide: it switches on kappa-opioid receptors, which dial down itch, but it is built to stay mostly outside the brain, so it eases itching without the high, sedation, or addiction risk of typical opioids.
The evidence base
12 cited references.
Regulatory & labels1
Vifor (International), Inc. (FDA label) · 2025
Registered trials4
ClinicalTrials.gov · PHASE2 · RECRUITING · 2026-06-17
ClinicalTrials.gov · NA · NOT_YET_RECRUITING · 2026-04-26
ClinicalTrials.gov · PHASE3 · COMPLETED · 2023-05-18
ClinicalTrials.gov · PHASE3 · TERMINATED · 2022-05-17
Indexed literature (PubMed)7
Fishbane S et al. · N Engl J Med · 2020
Ko MJ et al. · Kidney Res Clin Pract · 2023
Deeks ED · Drugs · 2021
Fugal J et al. · Ann Pharmacother · 2023
Cai X et al. · Front Pharmacol · 2024
Pilla JE et al. · 2026
Rastogi A et al. · Expert Rev Clin Pharmacol · 2023
Keep reading